Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
200 shown of 6,768 total abstracts
  1. Abstract 15582026-06-05 · 16:30 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-290 study)
    S. Tolaney, E. Winer · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract 99252026-06-02 · 21:00 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    J. Cortes, F. Andre, N. Rizvi, et al. · Royal Marsden Hospital
    Poster Discussion SessionMelanoma📄🖼️
  3. Abstract 12692026-06-01 · 15:00 CT · S406
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-64 study)
    H. Borghaei, S. Modi, T. Mok, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  4. Abstract 95802026-06-01 · 20:00 CT · E450
    PACIFIC-712: Imfinzi (durvalumab) adjuvant in SCLC
    L. Paz-Ares, P. Schmid, C. Saura · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  5. Abstract 49132026-06-02 · 14:15 CT · Hall B1
    Long-term follow-up of Imfinzi neoadjuvant for biliary tract: PACIFIC-310
    N. Rizvi, L. Paz-Ares, R. Herbst · University of Chicago
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  6. Abstract 10592026-06-01 · 13:30 CT · S100A
    PALOMA-577: Ibrance (palbociclib) 2L in HR+ breast cancer
    S. Antonia, M.C. Garassino, P. Schmid · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract 44212026-06-03 · 16:45 CT · Arie Crown Theater
    IMpower-799: Tecentriq (atezolizumab) 3L+ in HCC
    P. Schmid, E. Winer, S. Modi · Institut Gustave Roussy
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  8. Abstract 15272026-06-02 · 15:45 CT · S406
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    S. Modi, S. Tolaney, S. Peters · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract 99582026-06-02 · 16:30 CT · S100A
    IMpower-775: Tecentriq (atezolizumab) maintenance in NSCLC
    J. Brahmer, M. Krop · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  10. Abstract 16212026-06-03 · 18:00 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    S. Peters, R. Herbst, M.C. Garassino, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  11. Abstract 61592026-06-04 · 13:15 CT · S406
    Real-world effectiveness of Opdivo vs standard of care in RCC
    C. Robert, C. Saura, R. Herbst, et al. · MD Anderson Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  12. Abstract 44502026-06-05 · 20:00 CT · Arie Crown Theater
    Long-term follow-up of Enhertu maintenance for gastric: DESTINY-Breast-957
    C. Robert, S. Modi, M. Reck, et al. · Chinese University of Hong Kong
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  13. Abstract 11042026-06-04 · 20:00 CT · E450
    OlympiA-933: Lynparza (olaparib) neoadjuvant in HR+ breast cancer
    S. Modi, A. Spira · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract 14742026-06-04 · 16:45 CT · E450
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    P. Schmid, S. Modi, R. Herbst · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract 52842026-06-03 · 13:00 CT · Hall B1
    OlympiA-373: Lynparza (olaparib) 1L in prostate
    C. Robert, H. Borghaei, J. Brahmer · University of Chicago
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  16. Abstract 15682026-06-02 · 21:45 CT · S406
    MONALEESA-339: Kisqali (ribociclib) maintenance in HR+ breast cancer
    S. Tolaney, J. Cortes, L. Paz-Ares · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  17. Abstract 12912026-06-04 · 18:45 CT · S100A
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-407 study)
    J. Brahmer, C. Saura, P. Schmid, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 47112026-06-05 · 20:45 CT · S406
    DESTINY-Breast-950: Enhertu (trastuzumab deruxtecan) 3L+ in gastric
    S. Modi, N. Rizvi, A. Spira, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  19. Abstract 57372026-06-04 · 20:45 CT · E450
    Biomarker subgroup analysis of Lynparza in ovarian (the OlympiA-101 study)
    E. Winer, S. Peters · Dana-Farber Cancer Institute
    Poster Discussion SessionGynecologic Cancer📄🖼️
  20. Abstract 95272026-06-05 · 15:15 CT · E450
    Quality of life outcomes with Tagrisso in patients with NSCLC
    M.C. Garassino, S. Peters, A. Spira · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  21. Abstract 18502026-06-05 · 15:00 CT · E450
    MONARCH-185: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    C. Saura, G. Curigliano, N. Rizvi, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  22. Abstract 100072026-06-02 · 15:30 CT · E450
    CheckMate-230: Opdivo (nivolumab) maintenance in metastatic melanoma
    S. Antonia, C. Saura, P. Schmid, et al. · Massachusetts General Hospital
    Poster Discussion SessionMelanoma📄🖼️
  23. Abstract 16502026-06-01 · 21:00 CT · Arie Crown Theater
    MONALEESA-65: Kisqali (ribociclib) maintenance in HR+ breast cancer
    E. Winer, N. Rizvi, C. Robert, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  24. Abstract 18642026-06-04 · 20:30 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-879
    H. Rugo, H. Borghaei, G. Curigliano · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  25. Abstract 103842026-06-04 · 14:00 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    A. Spira, J. Cortes, S. Modi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  26. Abstract 91462026-06-02 · 13:30 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-145
    L. Paz-Ares, S. Tolaney, M. Reck · University of Chicago
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  27. Abstract 11672026-06-02 · 15:30 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-398
    S. Antonia, S. Modi, S. Tolaney, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  28. Abstract 18302026-06-01 · 13:45 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-618 study)
    C. Saura, C. Robert, M.C. Garassino, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract 47952026-06-01 · 20:15 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in gastric (the DESTINY-Breast-967 study)
    E. Winer, M. Krop, S. Tolaney · Royal Marsden Hospital
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  30. Abstract 67692026-06-03 · 18:15 CT · S406
    Long-term follow-up of Keytruda 3L+ for RCC: KEYNOTE-3
    J. Brahmer, S. Peters, A. Spira, et al. · Karolinska Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  31. Abstract 95812026-06-02 · 15:45 CT · S100A
    Quality of life outcomes with Keytruda in patients with SCLC
    A. Spira, H. Rugo, N. Rizvi · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  32. Abstract 12792026-06-05 · 20:00 CT · Hall B1
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    S. Tolaney, S. Peters, J. Brahmer, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  33. Abstract 10322026-06-04 · 13:30 CT · S100A
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    L. Paz-Ares, G. Curigliano, S. Tolaney, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  34. Abstract 19492026-06-02 · 21:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-416 study)
    H. Rugo, H. Borghaei, T. Mok, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  35. Abstract 46322026-06-04 · 13:00 CT · Hall B1
    Long-term follow-up of Trodelvy 3L+ for urothelial carcinoma: ASCENT-389
    M. Reck, F. Andre · Royal Marsden Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  36. Abstract 49802026-06-02 · 18:30 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-251
    C. Saura, N. Rizvi, S. Modi, et al. · National Cancer Center Japan
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  37. Abstract 92652026-06-03 · 20:30 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-329
    C. Saura, T. Mok · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  38. Abstract 61122026-06-04 · 21:30 CT · Arie Crown Theater
    Quality of life outcomes with Lynparza in patients with ovarian
    S. Peters, S. Modi, M. Krop, et al. · Stanford Cancer Institute
    Poster Discussion SessionGynecologic Cancer📄🖼️
  39. Abstract 49712026-06-03 · 19:30 CT · S406
    Real-world effectiveness of Tecentriq vs standard of care in HCC
    P. Schmid, F. Andre · MD Anderson Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  40. Abstract 46102026-06-03 · 13:30 CT · Arie Crown Theater
    Long-term follow-up of Enhertu adjuvant for gastric: DESTINY-Breast-634
    S. Peters, R. Herbst, J. Brahmer · MD Anderson Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  41. Abstract 18652026-06-04 · 21:15 CT · S406
    Long-term follow-up of Tecentriq adjuvant for TNBC: IMpower-970
    M. Reck, M.C. Garassino, S. Peters · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  42. Abstract 96932026-06-02 · 18:45 CT · Hall B1
    Long-term follow-up of Tecentriq 1L for NSCLC: IMpower-222
    S. Peters, G. Curigliano, S. Modi, et al. · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  43. Abstract 95862026-06-05 · 14:00 CT · S406
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    S. Peters, H. Rugo, C. Saura, et al. · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  44. Abstract 16472026-06-03 · 14:15 CT · S406
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    E. Winer, H. Borghaei · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  45. Abstract 47762026-06-02 · 19:45 CT · E450
    Real-world effectiveness of Enhertu vs standard of care in gastric
    J. Brahmer, S. Modi, T. Mok, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  46. Abstract 91362026-06-05 · 19:15 CT · S100A
    Long-term follow-up of Keytruda maintenance for SCLC: KEYNOTE-651
    C. Robert, A. Spira, F. Andre · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  47. Abstract 96052026-06-02 · 16:45 CT · E450
    CheckMate-777: Opdivo (nivolumab) adjuvant in metastatic melanoma
    L. Paz-Ares, T. Mok, H. Rugo · Chinese University of Hong Kong
    Poster Discussion SessionMelanoma📄🖼️
  48. Abstract 99302026-06-05 · 19:30 CT · S100A
    Quality of life outcomes with Imfinzi in patients with NSCLC
    C. Saura, G. Curigliano · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  49. Abstract 92282026-06-02 · 18:30 CT · Hall B1
    DESTINY-Breast-156: Enhertu (trastuzumab deruxtecan) 1L in NSCLC
    J. Cortes, S. Tolaney, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  50. Abstract 19282026-06-03 · 20:30 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-677 study)
    S. Tolaney, C. Robert · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  51. Abstract 93702026-06-02 · 16:15 CT · S406
    PACIFIC-614: Imfinzi (durvalumab) maintenance in NSCLC
    R. Herbst, M. Krop · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  52. Abstract 41392026-06-02 · 14:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-816 study)
    E. Winer, J. Cortes, M.C. Garassino, et al. · Stanford Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  53. Abstract 42992026-06-02 · 14:45 CT · Arie Crown Theater
    Quality of life outcomes with Tecentriq in patients with HCC
    A. Spira, E. Winer · Massachusetts General Hospital
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  54. Abstract 12202026-06-02 · 15:30 CT · E450
    KEYNOTE-413: Keytruda (pembrolizumab) maintenance in TNBC
    S. Peters, L. Paz-Ares, H. Borghaei, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  55. Abstract 19892026-06-01 · 13:15 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-582 study)
    M.C. Garassino, R. Herbst · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  56. Abstract 99302026-06-01 · 16:30 CT · S100A
    FLAURA-844: Tagrisso (osimertinib) 2L in NSCLC
    S. Peters, H. Rugo, E. Winer · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  57. Abstract 14932026-06-01 · 18:30 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-317
    M. Krop, F. Andre, H. Rugo, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  58. Abstract 18792026-06-04 · 14:30 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-131
    H. Rugo, N. Rizvi, L. Paz-Ares, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  59. Abstract 40792026-06-02 · 21:45 CT · E450
    Long-term follow-up of Padcev 2L for urothelial carcinoma: EV-101
    L. Paz-Ares, H. Borghaei, J. Brahmer · Chinese University of Hong Kong
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  60. Abstract 15852026-06-03 · 21:15 CT · S406
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    P. Schmid, M. Reck, H. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  61. Abstract 53442026-06-04 · 18:30 CT · S100A
    Long-term follow-up of Lynparza adjuvant for prostate: OlympiA-55
    S. Modi, S. Antonia, A. Spira, et al. · University of Chicago
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  62. Abstract 97232026-06-04 · 19:45 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-311
    A. Spira, G. Curigliano, N. Rizvi, et al. · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  63. Abstract 94342026-06-01 · 20:15 CT · S100A
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    M. Krop, R. Herbst, S. Peters, et al. · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  64. Abstract 94382026-06-03 · 15:45 CT · Arie Crown Theater
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    G. Curigliano, S. Modi, C. Robert, et al. · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  65. Abstract 90582026-06-03 · 15:15 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-661
    T. Mok, S. Peters · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  66. Abstract 48972026-06-05 · 15:00 CT · E450
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-860
    S. Antonia, M. Reck · Cleveland Clinic
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  67. Abstract 91532026-06-04 · 20:00 CT · Hall B1
    Quality of life outcomes with Enhertu in patients with NSCLC
    H. Borghaei, M. Krop · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  68. Abstract 46642026-06-05 · 19:15 CT · S406
    Real-world effectiveness of Trodelvy vs standard of care in urothelial carcinoma
    T. Mok, J. Cortes, C. Robert · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  69. Abstract 46812026-06-04 · 18:00 CT · E450
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-341 study)
    M. Krop, M.C. Garassino, M. Reck, et al. · National Cancer Center Japan
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  70. Abstract 49732026-06-05 · 16:15 CT · E450
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-437 study)
    S. Modi, A. Spira, C. Saura, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  71. Abstract 94922026-06-01 · 15:15 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    H. Rugo, M. Reck · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  72. Abstract 49622026-06-03 · 19:45 CT · Arie Crown Theater
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    T. Mok, J. Brahmer, N. Rizvi, et al. · Royal Marsden Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  73. Abstract 11362026-06-05 · 16:45 CT · S100A
    KEYNOTE-725: Keytruda (pembrolizumab) neoadjuvant in TNBC
    S. Peters, M. Reck, A. Spira, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  74. Abstract 41442026-06-01 · 13:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-735 study)
    R. Herbst, H. Borghaei, M.C. Garassino, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  75. Abstract 49112026-06-04 · 19:30 CT · E450
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    T. Mok, C. Saura, M. Krop · Peter MacCallum Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  76. Abstract 93972026-06-03 · 16:45 CT · Arie Crown Theater
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    E. Winer, S. Tolaney, P. Schmid · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  77. Abstract 93412026-06-01 · 20:00 CT · Hall B1
    Long-term follow-up of Enhertu maintenance for NSCLC: DESTINY-Breast-879
    H. Borghaei, C. Saura, N. Rizvi, et al. · University of Chicago
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  78. Abstract 64502026-06-03 · 13:45 CT · S100A
    Real-world effectiveness of Lynparza vs standard of care in ovarian
    J. Cortes, S. Peters, G. Curigliano, et al. · Massachusetts General Hospital
    Poster Discussion SessionGynecologic Cancer📄🖼️
  79. Abstract 56832026-06-01 · 20:00 CT · S406
    OlympiA-903: Lynparza (olaparib) adjuvant in prostate
    C. Saura, S. Peters, S. Tolaney, et al. · Chinese University of Hong Kong
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  80. Abstract 93472026-06-04 · 19:00 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-988
    L. Paz-Ares, H. Rugo, S. Antonia, et al. · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  81. Abstract 17172026-06-02 · 15:00 CT · S100A
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-848
    M.C. Garassino, S. Antonia, G. Curigliano, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  82. Abstract 90992026-06-03 · 16:15 CT · S406
    Quality of life outcomes with Tecentriq in patients with NSCLC
    C. Saura, R. Herbst, J. Cortes, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  83. Abstract 15612026-06-01 · 21:30 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-570
    S. Tolaney, L. Paz-Ares, F. Andre, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  84. Abstract 59722026-06-03 · 15:15 CT · Hall B1
    Quality of life outcomes with Lynparza in patients with prostate
    J. Brahmer, T. Mok, S. Modi · Massachusetts General Hospital
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  85. Abstract 91552026-06-02 · 15:30 CT · S406
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-153
    E. Winer, J. Cortes · Cleveland Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  86. Abstract 93172026-06-03 · 16:15 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-141 study)
    E. Winer, A. Spira · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  87. Abstract 44522026-06-02 · 20:00 CT · S406
    Long-term follow-up of Tecentriq neoadjuvant for HCC: IMpower-725
    P. Schmid, J. Cortes, S. Antonia, et al. · Karolinska Institute
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  88. Abstract 15512026-06-02 · 13:00 CT · E450
    MONARCH-52: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    P. Schmid, A. Spira, J. Cortes, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  89. Abstract 99522026-06-04 · 13:00 CT · S100A
    PACIFIC-398: Imfinzi (durvalumab) 3L+ in NSCLC
    S. Peters, A. Spira · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  90. Abstract 92432026-06-02 · 14:30 CT · S100A
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-243
    J. Cortes, J. Brahmer, E. Winer · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  91. Abstract 15982026-06-01 · 18:00 CT · Arie Crown Theater
    Long-term follow-up of Enhertu 2L for HR+ breast cancer: DESTINY-Breast-179
    L. Paz-Ares, S. Antonia · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  92. Abstract 41762026-06-01 · 21:15 CT · S100A
    Long-term follow-up of Padcev neoadjuvant for urothelial carcinoma: EV-825
    L. Paz-Ares, J. Cortes, J. Brahmer · Stanford Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  93. Abstract 13422026-06-03 · 15:45 CT · S100A
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-337
    M.C. Garassino, N. Rizvi, J. Brahmer · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  94. Abstract 92472026-06-01 · 16:15 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-72 study)
    J. Cortes, L. Paz-Ares, C. Robert, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  95. Abstract 14872026-06-02 · 21:45 CT · Arie Crown Theater
    MONARCH-397: Verzenio (abemaciclib) 2L in HR+ breast cancer
    M. Krop, H. Borghaei, S. Peters · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  96. Abstract 90192026-06-01 · 18:15 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-454
    S. Tolaney, T. Mok, M. Reck, et al. · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  97. Abstract 98472026-06-05 · 14:45 CT · S406
    IMpower-549: Tecentriq (atezolizumab) adjuvant in NSCLC
    C. Saura, J. Cortes, S. Antonia, et al. · University of Chicago
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  98. Abstract 10932026-06-04 · 20:00 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-305
    A. Spira, M. Reck, J. Cortes · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  99. Abstract 98202026-06-05 · 20:15 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-150
    N. Rizvi, S. Modi · University of Chicago
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  100. Abstract 14332026-06-03 · 18:30 CT · Arie Crown Theater
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    A. Spira, C. Robert, M.C. Garassino, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  101. Abstract 17052026-06-01 · 13:45 CT · S100A
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-102
    G. Curigliano, H. Borghaei, T. Mok, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  102. Abstract 47152026-06-04 · 14:45 CT · E450
    IMpower-966: Tecentriq (atezolizumab) maintenance in HCC
    S. Tolaney, A. Spira, P. Schmid · Stanford Cancer Institute
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  103. Abstract 100152026-06-02 · 20:15 CT · S406
    KEYNOTE-319: Keytruda (pembrolizumab) 1L in metastatic melanoma
    M. Krop, H. Rugo, R. Herbst, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  104. Abstract 62492026-06-02 · 20:30 CT · S100A
    Long-term follow-up of Keytruda adjuvant for RCC: KEYNOTE-557
    C. Saura, R. Herbst, S. Modi, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  105. Abstract 47512026-06-04 · 15:45 CT · S100A
    EV-288: Padcev (enfortumab vedotin) neoadjuvant in urothelial carcinoma
    P. Schmid, S. Modi, S. Antonia · National Cancer Center Japan
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  106. Abstract 48082026-06-05 · 13:45 CT · S406
    Quality of life outcomes with Enhertu in patients with gastric
    S. Peters, A. Spira · Chinese University of Hong Kong
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  107. Abstract 15022026-06-02 · 13:00 CT · E450
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-103
    H. Borghaei, H. Rugo, E. Winer, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  108. Abstract 97982026-06-04 · 14:45 CT · E450
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-157
    S. Tolaney, N. Rizvi, T. Mok · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  109. Abstract 59882026-06-03 · 13:00 CT · E450
    OlympiA-862: Lynparza (olaparib) maintenance in prostate
    E. Winer, L. Paz-Ares, H. Borghaei, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  110. Abstract 43282026-06-02 · 19:30 CT · Hall B1
    EV-467: Padcev (enfortumab vedotin) adjuvant in urothelial carcinoma
    J. Brahmer, S. Tolaney, M. Krop, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  111. Abstract 16972026-06-05 · 20:00 CT · S406
    PALOMA-316: Ibrance (palbociclib) 1L in HR+ breast cancer
    R. Herbst, E. Winer · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  112. Abstract 96672026-06-02 · 14:00 CT · S100A
    KEYNOTE-783: Keytruda (pembrolizumab) 3L+ in NSCLC
    M. Krop, S. Peters, S. Antonia · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  113. Abstract 47342026-06-03 · 18:15 CT · S406
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-207
    J. Brahmer, P. Schmid, A. Spira · MD Anderson Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  114. Abstract 48172026-06-03 · 15:45 CT · S100A
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-390
    N. Rizvi, C. Robert, H. Borghaei, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  115. Abstract 11742026-06-03 · 19:45 CT · Arie Crown Theater
    PALOMA-918: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    F. Andre, A. Spira · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  116. Abstract 40072026-06-03 · 14:15 CT · S406
    Long-term follow-up of Opdivo 3L+ for HCC: CheckMate-780
    J. Brahmer, S. Antonia · Institut Gustave Roussy
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  117. Abstract 45642026-06-01 · 14:45 CT · Arie Crown Theater
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-428
    C. Saura, M. Reck, J. Brahmer · Karolinska Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  118. Abstract 95032026-06-05 · 14:30 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-61
    N. Rizvi, E. Winer, C. Robert, et al. · Cleveland Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  119. Abstract 40402026-06-02 · 19:30 CT · Arie Crown Theater
    Quality of life outcomes with Trodelvy in patients with urothelial carcinoma
    J. Cortes, S. Antonia, E. Winer, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  120. Abstract 90502026-06-02 · 20:45 CT · S100A
    Quality of life outcomes with Imfinzi in patients with SCLC
    C. Robert, L. Paz-Ares, P. Schmid, et al. · Mayo Clinic
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  121. Abstract 13822026-06-04 · 13:30 CT · S100A
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    P. Schmid, M. Reck, J. Cortes, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  122. Abstract 96482026-06-05 · 16:30 CT · E450
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    L. Paz-Ares, H. Rugo, S. Tolaney · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionMelanoma📄🖼️
  123. Abstract 48822026-06-04 · 14:15 CT · E450
    Long-term follow-up of Padcev maintenance for urothelial carcinoma: EV-705
    M. Krop, E. Winer, M.C. Garassino · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  124. Abstract 40912026-06-02 · 14:15 CT · Arie Crown Theater
    DESTINY-Breast-914: Enhertu (trastuzumab deruxtecan) 3L+ in gastric
    M. Krop, S. Peters · Institut Gustave Roussy
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  125. Abstract 16582026-06-04 · 14:15 CT · S100A
    ASCENT-160: Trodelvy (sacituzumab govitecan) maintenance in TNBC
    M. Reck, A. Spira, C. Saura · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  126. Abstract 47042026-06-02 · 16:30 CT · S406
    Long-term follow-up of Trodelvy 3L+ for urothelial carcinoma: ASCENT-618
    H. Rugo, N. Rizvi, L. Paz-Ares, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  127. Abstract 11922026-06-01 · 19:45 CT · Arie Crown Theater
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    H. Borghaei, F. Andre, C. Saura, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  128. Abstract 64312026-06-03 · 21:15 CT · S100A
    Biomarker subgroup analysis of Lynparza in ovarian (the OlympiA-695 study)
    J. Cortes, R. Herbst, M. Krop, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionGynecologic Cancer📄🖼️
  129. Abstract 48572026-06-05 · 18:00 CT · Hall B1
    Long-term follow-up of Enhertu adjuvant for gastric: DESTINY-Breast-352
    S. Antonia, J. Cortes, P. Schmid, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  130. Abstract 96252026-06-02 · 20:15 CT · S406
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-82
    S. Peters, M. Reck, M.C. Garassino, et al. · Mayo Clinic
    Poster Discussion SessionMelanoma📄🖼️
  131. Abstract 99202026-06-02 · 19:45 CT · E450
    CheckMate-860: Opdivo (nivolumab) maintenance in NSCLC
    N. Rizvi, R. Herbst · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  132. Abstract 44412026-06-03 · 18:00 CT · S100A
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-252 study)
    A. Spira, H. Rugo, H. Borghaei · Royal Marsden Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  133. Abstract 60552026-06-01 · 20:30 CT · S406
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-422
    R. Herbst, S. Peters, F. Andre · Institut Gustave Roussy
    Poster Discussion SessionGynecologic Cancer📄🖼️
  134. Abstract 90592026-06-03 · 20:00 CT · E450
    Long-term follow-up of Keytruda 3L+ for SCLC: KEYNOTE-651
    S. Antonia, M. Krop, T. Mok · Karolinska Institute
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  135. Abstract 46392026-06-03 · 21:30 CT · E450
    ASCENT-733: Trodelvy (sacituzumab govitecan) maintenance in urothelial carcinoma
    C. Robert, H. Rugo, R. Herbst, et al. · Stanford Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  136. Abstract 95192026-06-02 · 20:00 CT · S100A
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-602
    H. Borghaei, M. Reck · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  137. Abstract 95992026-06-03 · 13:30 CT · E450
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-737
    M.C. Garassino, S. Peters, J. Brahmer · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  138. Abstract 15932026-06-01 · 19:15 CT · E450
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-964
    J. Brahmer, C. Robert, L. Paz-Ares, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  139. Abstract 40792026-06-03 · 20:45 CT · E450
    IMpower-862: Tecentriq (atezolizumab) neoadjuvant in HCC
    C. Robert, M.C. Garassino, H. Borghaei, et al. · MD Anderson Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  140. Abstract 17662026-06-03 · 16:30 CT · E450
    Long-term follow-up of Lynparza 3L+ for HR+ breast cancer: OlympiA-839
    M. Krop, E. Winer · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  141. Abstract 90062026-06-02 · 18:15 CT · E450
    Quality of life outcomes with Keytruda in patients with NSCLC
    N. Rizvi, S. Tolaney, C. Robert · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  142. Abstract 45802026-06-02 · 16:00 CT · S406
    EV-788: Padcev (enfortumab vedotin) 2L in urothelial carcinoma
    H. Rugo, E. Winer, G. Curigliano, et al. · Royal Marsden Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  143. Abstract 14582026-06-05 · 16:30 CT · S100A
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    R. Herbst, A. Spira, M.C. Garassino · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  144. Abstract 90712026-06-03 · 14:30 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-696
    J. Brahmer, L. Paz-Ares, T. Mok, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  145. Abstract 12812026-06-04 · 16:30 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-803 study)
    C. Saura, H. Borghaei, G. Curigliano, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  146. Abstract 63732026-06-04 · 20:00 CT · Hall B1
    Quality of life outcomes with Opdivo in patients with RCC
    S. Antonia, L. Paz-Ares, C. Robert · Mayo Clinic
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  147. Abstract 93462026-06-02 · 20:45 CT · Arie Crown Theater
    Long-term follow-up of Imfinzi 1L for NSCLC: PACIFIC-305
    S. Antonia, P. Schmid, R. Herbst · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  148. Abstract 47222026-06-05 · 16:00 CT · S406
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-802 study)
    R. Herbst, E. Winer, H. Borghaei, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  149. Abstract 55702026-06-04 · 14:45 CT · E450
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-909
    J. Cortes, G. Curigliano, C. Robert · Mayo Clinic
    Poster Discussion SessionGynecologic Cancer📄🖼️
  150. Abstract 10572026-06-02 · 15:45 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-283
    H. Borghaei, S. Modi, L. Paz-Ares · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  151. Abstract 66002026-06-02 · 13:30 CT · S100A
    Real-world effectiveness of Keytruda vs standard of care in RCC
    F. Andre, E. Winer, P. Schmid, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  152. Abstract 11442026-06-02 · 18:00 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-992 study)
    F. Andre, T. Mok · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  153. Abstract 98292026-06-02 · 13:45 CT · S100A
    KEYNOTE-707: Keytruda (pembrolizumab) adjuvant in metastatic melanoma
    C. Robert, L. Paz-Ares · Massachusetts General Hospital
    Poster Discussion SessionMelanoma📄🖼️
  154. Abstract 19542026-06-05 · 20:15 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-531
    J. Brahmer, C. Saura, M. Krop, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  155. Abstract 99602026-06-04 · 14:30 CT · Arie Crown Theater
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    M. Reck, J. Cortes, S. Modi, et al. · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  156. Abstract 47892026-06-02 · 21:15 CT · S100A
    Long-term follow-up of Enhertu 1L for gastric: DESTINY-Breast-615
    S. Tolaney, P. Schmid · Karolinska Institute
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  157. Abstract 42872026-06-04 · 13:45 CT · S406
    Real-world effectiveness of Imfinzi vs standard of care in biliary tract
    M.C. Garassino, S. Tolaney, N. Rizvi, et al. · Cleveland Clinic
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  158. Abstract 42232026-06-01 · 18:15 CT · S406
    Long-term follow-up of Opdivo neoadjuvant for HCC: CheckMate-442
    S. Antonia, S. Tolaney, P. Schmid · Dana-Farber Cancer Institute
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  159. Abstract 49162026-06-05 · 21:45 CT · Arie Crown Theater
    Long-term follow-up of Padcev adjuvant for urothelial carcinoma: EV-479
    J. Cortes, P. Schmid, G. Curigliano, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  160. Abstract 43962026-06-02 · 21:45 CT · Hall B1
    Long-term follow-up of Tecentriq neoadjuvant for HCC: IMpower-913
    C. Robert, R. Herbst, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  161. Abstract 50272026-06-04 · 14:45 CT · E450
    Long-term follow-up of Lynparza maintenance for prostate: OlympiA-795
    N. Rizvi, G. Curigliano, A. Spira · Dana-Farber Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  162. Abstract 10042026-06-05 · 16:30 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-105 study)
    P. Schmid, S. Antonia, C. Saura, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  163. Abstract 92742026-06-03 · 15:00 CT · E450
    Long-term follow-up of Imfinzi 1L for NSCLC: PACIFIC-819
    C. Robert, M. Reck, M.C. Garassino, et al. · University of Chicago
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  164. Abstract 15862026-06-03 · 20:15 CT · Arie Crown Theater
    Quality of life outcomes with Trodelvy in patients with TNBC
    T. Mok, J. Cortes · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  165. Abstract 44632026-06-01 · 14:00 CT · Hall B1
    Long-term follow-up of Enhertu 3L+ for gastric: DESTINY-Breast-421
    P. Schmid, J. Brahmer, N. Rizvi, et al. · Mayo Clinic
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  166. Abstract 17932026-06-03 · 21:15 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-206
    H. Rugo, J. Cortes, S. Modi · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  167. Abstract 57192026-06-05 · 15:30 CT · E450
    Long-term follow-up of Lynparza adjuvant for ovarian: OlympiA-9
    H. Borghaei, E. Winer, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionGynecologic Cancer📄🖼️
  168. Abstract 91552026-06-01 · 13:00 CT · S406
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-692
    S. Peters, S. Tolaney, A. Spira, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  169. Abstract 96252026-06-03 · 19:00 CT · Hall B1
    Long-term follow-up of Tecentriq 2L for NSCLC: IMpower-620
    A. Spira, C. Robert, H. Rugo, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  170. Abstract 14062026-06-05 · 15:45 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-270 study)
    G. Curigliano, S. Tolaney · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  171. Abstract 92942026-06-01 · 15:00 CT · S406
    PACIFIC-939: Imfinzi (durvalumab) 2L in NSCLC
    H. Rugo, L. Paz-Ares, C. Robert · Cleveland Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  172. Abstract 18182026-06-05 · 21:45 CT · Hall B1
    PALOMA-389: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    N. Rizvi, G. Curigliano · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  173. Abstract 10802026-06-02 · 19:15 CT · S100A
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-260
    M.C. Garassino, J. Brahmer, N. Rizvi, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  174. Abstract 16052026-06-02 · 13:30 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-912 study)
    G. Curigliano, H. Borghaei, N. Rizvi · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  175. Abstract 12192026-06-05 · 20:00 CT · Arie Crown Theater
    DESTINY-Breast-34: Enhertu (trastuzumab deruxtecan) 2L in HR+ breast cancer
    S. Tolaney, G. Curigliano, H. Borghaei, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  176. Abstract 95072026-06-04 · 16:45 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-296
    S. Peters, M. Reck, E. Winer, et al. · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  177. Abstract 99622026-06-01 · 21:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-130 study)
    E. Winer, C. Robert, M. Reck, et al. · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  178. Abstract 97332026-06-02 · 13:15 CT · S406
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-455
    C. Saura, S. Tolaney, F. Andre · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  179. Abstract 19052026-06-02 · 18:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-629 study)
    J. Brahmer, S. Modi, M. Reck, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  180. Abstract 47052026-06-02 · 21:00 CT · Hall B1
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-576
    T. Mok, J. Cortes · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  181. Abstract 49972026-06-02 · 21:15 CT · S406
    Long-term follow-up of Opdivo 1L for HCC: CheckMate-779
    S. Peters, G. Curigliano, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  182. Abstract 12272026-06-02 · 19:30 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-563
    H. Rugo, J. Brahmer, F. Andre, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  183. Abstract 63952026-06-02 · 19:15 CT · Hall B1
    OlympiA-339: Lynparza (olaparib) maintenance in ovarian
    S. Modi, S. Peters, E. Winer · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionGynecologic Cancer📄🖼️
  184. Abstract 96402026-06-03 · 19:30 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-824
    E. Winer, R. Herbst, M. Reck, et al. · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  185. Abstract 43622026-06-03 · 14:45 CT · E450
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-51
    M.C. Garassino, R. Herbst, C. Robert, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  186. Abstract 19632026-06-03 · 20:30 CT · Arie Crown Theater
    DESTINY-Breast-312: Enhertu (trastuzumab deruxtecan) 3L+ in HR+ breast cancer
    M. Krop, S. Peters, T. Mok · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  187. Abstract 91232026-06-03 · 16:30 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-300
    T. Mok, E. Winer, N. Rizvi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  188. Abstract 95942026-06-01 · 16:30 CT · E450
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-918
    G. Curigliano, C. Saura, J. Cortes, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  189. Abstract 18192026-06-05 · 13:45 CT · Hall B1
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    S. Tolaney, M. Krop, M. Reck, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  190. Abstract 93922026-06-02 · 21:15 CT · S406
    FLAURA-324: Tagrisso (osimertinib) maintenance in NSCLC
    S. Modi, F. Andre, P. Schmid, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  191. Abstract 48022026-06-03 · 15:45 CT · E450
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-226 study)
    H. Borghaei, M. Reck, F. Andre, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  192. Abstract 14602026-06-05 · 16:30 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-740
    T. Mok, F. Andre, M.C. Garassino, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  193. Abstract 41342026-06-03 · 21:15 CT · S406
    Quality of life outcomes with Opdivo in patients with HCC
    T. Mok, R. Herbst, C. Saura · University of Chicago
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  194. Abstract 68332026-06-03 · 19:45 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-657
    T. Mok, M. Reck, L. Paz-Ares · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  195. Abstract 41682026-06-02 · 18:15 CT · E450
    EV-364: Padcev (enfortumab vedotin) adjuvant in urothelial carcinoma
    T. Mok, G. Curigliano · Princess Margaret Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  196. Abstract 45962026-06-03 · 21:30 CT · S406
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-216
    S. Modi, S. Peters · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  197. Abstract 16962026-06-02 · 14:00 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-770 study)
    C. Robert, T. Mok, A. Spira, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  198. Abstract 17542026-06-03 · 21:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-443 study)
    T. Mok, H. Rugo, M. Reck, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  199. Abstract 14222026-06-05 · 14:30 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-706
    R. Herbst, E. Winer · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  200. Abstract 12412026-06-01 · 16:15 CT · Hall B1
    Long-term follow-up of Trodelvy maintenance for TNBC: ASCENT-820
    R. Herbst, S. Antonia · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.